

Table 9.25
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	169,687	68.1 (67.8 , 68.4)	89.0 (88.3 , 89.7)	75.8 (75.4 , 76.1)	57.4 (56.9 , 57.9)			
1 Hodgkin Lymphoma	14,949	85.3 (84.6 , 86.0)	96.4 (95.3 , 97.3)	89.4 (88.7 , 90.1)	52.8 (49.9 , 55.6)			
1(a) Classical Hodgkin lymphoma	14,242	84.8 (84.1 , 85.5)	96.2 (95.0 , 97.1)	89.0 (88.3 , 89.7)	51.6 (48.5 , 54.6)			
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	2,369	79.7 (77.6 , 81.6)	96.4 (92.4 , 98.3)	86.0 (83.9 , 87.9)	54.9 (49.1 , 60.3)			
1(a)1.1 Lymphocyte-rich	482	87.1 (82.2 , 90.7)	100.0 (- , -)	91.2 (86.6 , 94.2)	66.6 (50.7 , 78.4)			
1(a)1.2 Mixed cellularity	1,697	80.0 (77.5 , 82.2)	94.9 (89.3 , 97.6)	86.0 (83.4 , 88.1)	56.5 (49.6 , 62.7)			
1(a)1.3 Lymphocyte-depleted	190	56.6 (47.8 , 64.4)	- (- , -)	70.2 (59.5 , 78.6)	26.0 (13.1 , 40.9)			
1(a)2. Nodular sclerosis	8,816	89.4 (88.6 , 90.2)	96.1 (94.7 , 97.1)	91.7 (90.8 , 92.5)	55.6 (50.4 , 60.4)			
1(a)3. Classical Hodgkin lymphoma, NOS ^c	3,057	75.2 (73.3 , 77.0)	96.6 (92.4 , 98.5)	82.7 (80.7 , 84.5)	43.9 (39.2 , 48.5)			
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	707	95.3 (92.4 , 97.2)	100.0 (- , -)	96.4 (93.4 , 98.0)	78.8 (59.2 , 89.8)			
2 Non-Hodgkin lymphoma	150,164	66.9 (66.6 , 67.3)	87.0 (86.1 , 87.8)	74.0 (73.5 , 74.4)	58.1 (57.6 , 58.7)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	83	60.1 (45.8 , 71.7)	- (- , -)	63.5 (46.1 , 76.6)	53.4 (29.0 , 72.7)			
4 Lymphoid neoplasm, NOS ^c	4,491	48.8 (46.9 , 50.7)	84.5 (72.3 , 91.6)	61.4 (58.6 , 64.0)	39.8 (37.2 , 42.4)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.